Perioperative Telemonitoring Yields “Encouraging” Results in GI Cancers

Commentary
Video

Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.

The use of perioperative telemonitoring and nursing triage may have a positive impact on the recovery of patients who undergo gastrointestinal (GI) oncologic surgery, according to Kelly M. Mahuron, MD.

Mahuron, a complex general surgical oncology fellow in the Department of Surgical Oncology at City of Hope National Medical Center in Duarte, California, spoke with CancerNetwork® during the 2024 Society of Surgical Oncology Annual Meeting (SSO) about findings from a prospective randomized trial assessing whether telemonitoring in combination with nursing triage intervention affected surgical outcomes and recovery in patients with GI cancers.

According to Mahuron, the use of perioperative telemonitoring correlated with improvements in quality of life following surgery. Additionally, she discussed how the telemonitoring tool may be feasible to use in combination with nursing support among patients in a community setting.

Transcript:

As reflected in our high rates of retention and our low attrition rate, perioperative telemonitoring was found to be very feasible and accessible to patients. Looking at the efficacy data, we did not find a difference in study arms in complications or readmissions. But we did find a difference in patient-reported outcomes involving quality of life. We used The MD Anderson Symptom Inventory, which is a well-established and validated patient-reported outcome measurement tool, to look at the severity of patient symptoms as well as interference of their symptoms upon their activity levels.

Compared with the control arm, the telemonitoring intervention arm reported significantly lower symptom severity scores at postoperative days 14 and 30, and [patients in the telemonitoring arm] also had lower activity interference scores at postoperative days 7, 14, and 30. These findings suggest that telemonitoring with nursing triage may have a positive impact on their recovery.

This was done at a single institution, and [City of Hope is] more of an academic setting. But in the community, there are a lot of patients who have varying levels of resources at home. Perioperative telemonitoring with nursing support may be a very feasible means to help bridge the gap and give additional recovery support to these patients.

In addition to determining the optimal timing and duration of telemonitoring, we’re actively working to determine which subsets of patients might benefit the most. The study has produced really encouraging results, and we’re grateful for all the hard work of the team and to all the patients who agreed to participate.

Reference

Mauhron KM, Esslin P, Sun V, et al. Randomized controlled trial - perioperative telemonitoring of patient generated health data in gastrointestinal oncologic surgery: assessing outcomes. Presented at: Society of Surgical Oncology (SSO) 2024 Annual Meeting; March 20-23, 2024; Atlanta, GA. Abstract P55.

Recent Videos
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
BCMA testing tracks clinical changes faster without the need for marker expression vs monoclonal immunoglobulin, a conventional multiple myeloma marker.
Studies indicate that higher BCMA levels are associated with a greater need for therapy years following diagnosis for patients with smoldering myeloma.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Related Content